Celgene Corporation's Anthrax Immune Globulin Delivered and Accepted Into U.S. Strategic National Stockpile
TORONTO and WINNIPEG, Aug. 29 /CNW/ - Cangene Corporation today reports
that it has completed delivery of the initial order for anthrax immune
globulin and the drug has been formally received into the U.S. Strategic
National Stockpile ("SNS"). This acceptance of product into the SNS by the
U.S. Department of Health and Human Services (managed by the U.S. Biomedical
Advanced Research and Development Authority ("BARDA") within HHS) confirms
that Cangene can proceed to invoice for approximately one third of the
previously disclosed $US18-22 million total; the remainder will be invoiced
shortly, when delivery of the botulism toxin immune globulin has similarly
been completed.